Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inverness results

This article was originally published in The Tan Sheet

Executive Summary

FY 2003 net revenues jumped 42.5% to $296.4 mil., while fourth quarter net sales rose to $93.5 mil. from $65.1 mil in prior-year period, Inverness announces Feb. 18. The increases are primarily attributable to acquired businesses, the June launch of ClearBlue digital pregnancy test and the acquisition of Abbott Labs test kit lines, including Fact plus home pregnancy tests, Waltham, Mass.-based firm says. Inverness acquired products in September (1"The Tan Sheet" Oct. 6, 2003, p. 13)...

You may also be interested in...



Inverness Expands Home Pregnancy Market Share With Fact Plus Acquisition

Inverness Medical Innovations will immediately take over distribution of Abbott Labs' Fact plus OTC home pregnancy tests after acquiring the line along with several professional test kit products from the firm in a $92.5 mil. deal

Mylan Weighs In On Coronavirus Drug Shortage Concerns

Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business. 

 

Eyes On Pricing As Zolgensma Moves Closer To Japan Market

Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.

Topics

UsernamePublicRestriction

Register

PS096509

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel